Synthetic Biologics announces issuance of US Patent for the use of Oral Estriol -Trimesta™ for treatment of Multiple Sclerosis & other Autoimmune Diseases
Synthetic Biologics, Inc., a developer of anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and other diseases, announced today that the U.S. Patent & Trademark Office has issued U.S. Patent No. 8,658,627 entitled, Pregnancy Hormone Combination for Treatment of Autoimmune Diseases, to the Regents of the University of California (UCLA).
